Within the community, Δ9-THCA-dominant cannabis extracts are being used to treat Dravet syndrome patients even in the absence of evidence supporting its efficacy.8,9 In this study, highly purified Δ9-THCA had no effect on hyperthermia-induced seizures in the Scn1a+/− mouse model of Dravet syndrome despite Δ9-THCA attaining >1 μM brain concentrations. The gene discussed is SCN1A; the disease is Dravet syndrome.